Literature DB >> 26862650

IMMUNOLOGICAL PROFILES IN HIV POSITIVE PATIENTS FOLLOWING HAART INITIATION IN KIGALI, RWANDA.

A P Twizerimana, J Mwatha, J P Musabyimana, E Kayigi, J De Dieu Harelimana, S M Karanja, L Mutesa.   

Abstract

BACKGROUND: Interleukin-10, IL-2 and IFN-γ are some of the crucial cytokines associated with HIV infection and pathogenesis. While IL-2 and IFN-γ play critical roles in host resistance to infection, IL-10 inhibits the synthesis IFN-γ, IL-2 at mRNA and protein level; exacerbating damage to immune system.
OBJECTIVE: To determine the levels of, changes in and correlation between CD4 count, viral load, IL-10, IL-2 and IFN-γ before HAART and at six months of HAART among HIV positive patients in Kigali; with a view to understand cytokine networks particularly in relation to HAART; and to see whether they can be used as alternative markers of the disease progression.
DESIGN: Longitudinal study.
SETTING: Kagugu, Kimironko, Biryogo, Gitega Health Centres and Centre Medico-Social Cornum; all located in Kigali.
SUBJECTS: Thirty three (33) HAART initiation eligible HIV positive patients including 13 women and 20 men.
RESULTS: A drop in viral load (though only a small number of patients achieved an undetectable viraemia); a recovery of CD4+ cells, a decrease in IL-10 (though it remained high for many patients especially those with unchanged viraemia); and an increase in IL-2 and IFN-γ indicated a successful HAART. A negative correlation between CD4 count and viral load and between CD4 count and IL-10 (but r < -0.5) was observed. IL-10 correlated positively and strongly with viremia (r > 0.5 at both time points: p-values < 0.05). There was no significant correlation between CD4 count, IL-2 and IFN-y.
CONCLUSION: Results demonstrated the down-regulatory effect of IL-10 on Th1 cytokines and that a shift from Th1 to Th2 cytokine is associated with HIV disease progression. A successful HAART results in CD4+ cells recovery, drop in viraemia and IL-10 with up-regulation of Th1 cytokines. Also, findings show potential usefulness of IL-10 as a marker of HIV disease progression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 26862650

Source DB:  PubMed          Journal:  East Afr Med J        ISSN: 0012-835X


  4 in total

1.  Immunological Response During HAART and Determinants of Current CD4+ T-Cell Count Among HIV/AIDS Patients Attending University of Gondar Referral Hospital, Northwest Ethiopia.

Authors:  Gizachew Ayele Manaye; Dejene Derseh Abateneh; Kindie Mitiku Kebede; Alemayehu Sayih Belay
Journal:  HIV AIDS (Auckl)       Date:  2020-07-31

2.  CD4+ cells recovery in HIV positive patients with severe immunosuppression at HAART initiation at Centre Medico-Social Cor-Unum, Kigali.

Authors:  Nyiramana Marie Merci; Uwimana Emerence; Nzitakera Augustin; Michael Habtu; Ingabire Julie; Tuyishime Angelique; Beneyo Jessica; Akimana Cynthia; Augustin Twizerimana Penda
Journal:  Pan Afr Med J       Date:  2017-01-12

3.  Cardiovascular, endothelial function, and immune markers in response to treatment with a polysaccharide in HIV+ adults in a randomized, double-blind placebo-controlled trial.

Authors:  John E Lewis; Steven E Atlas; Muhammad H Abbas; Ammar Rasul; Ashar Farooqi; Laura A Lantigua; Frederick Michaud; Sharon Goldberg; Lucas C Lages; Jinrun Gao; Oscar L Higuera; Andrea Fiallo; Philip D Harvey; Eduard Tiozzo; Judi M Woolger; Stephanie Ciraula; Armando Mendez; Allan Rodriguez; Janet Konefal
Journal:  J Clin Transl Res       Date:  2020-04-13

4.  Interleukin-10 contributes to reservoir establishment and persistence in SIV-infected macaques treated with antiretroviral therapy.

Authors:  Justin Harper; Susan P Ribeiro; Chi Ngai Chan; Malika Aid; Claire Deleage; Luca Micci; Maria Pino; Barbara Cervasi; Gopalan Raghunathan; Eric Rimmer; Gulesi Ayanoglu; Guoxin Wu; Neeta Shenvi; Richard Jo Barnard; Gregory Q Del Prete; Kathleen Busman-Sahay; Guido Silvestri; Deanna A Kulpa; Steven E Bosinger; Kirk A Easley; Bonnie J Howell; Dan Gorman; Daria J Hazuda; Jacob D Estes; Rafick-Pierre Sekaly; Mirko Paiardini
Journal:  J Clin Invest       Date:  2022-04-15       Impact factor: 19.456

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.